Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: Results of the LEGEND-A pilot study

Ioannis I Spiliotis, Rod Chalk, Stephen Gough, Patrik Rorsman, Ioannis I Spiliotis, Rod Chalk, Stephen Gough, Patrik Rorsman

No abstract available

Keywords: antidiabetic drug; clinical trial; drug mechanism; experimental pharmacology; glucagon; type 2 diabetes.

Conflict of interest statement

IS, RC and PR declare that they have no competing interests. SG reports personal fees from Novo Nordisk A/S, Denmark, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Fasting plasma concentrations of glucagon and glucose, continuous glucose monitoring data showing percentage of time spent hypoglycaemic (glucose p < .05, **p < .001)

References

    1. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987;36(3):274‐283.
    1. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes. 2000;49(8):1367‐1373.
    1. Ashcroft FM, Rorsman P. K(ATP) channels and islet hormone secretion: new insights and controversies. Nat Rev Endocrinol. 2013;9(11):660‐669.
    1. Zhang Q, Ramracheya R, Lahmann C, et al. Role of KATP channels in glucose‐regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013;18(6):871‐882.
    1. Beltrand J, Godot C, Busiah K, et al. Glibentek, a new suspension of Glibenclamide for patients with neonatal diabetes, is as effective and more convenient than crushed tablets. Hormone Res Paediatr. 2016;86(suppl 1):1‐556.
    1. Campbell JE, Drucker DJ. Islet α cells and glucagon—critical regulators of energy homeostasis. Nat Rev Endocrinol. 2015;11(6):329‐338.
    1. Matsuda A, Kuzuya T, Sugita Y, Kawashima K. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res. 1983;15(9):425‐428.
    1. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon‐like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239‐1246.
    1. Rorsman P, Huising MO. The somatostatin‐secreting pancreatic delta‐cell in health and disease. Nat Rev Endocrinol. 2018;14(7):404‐414.
    1. Braun M, Ramracheya R, Amisten S, et al. Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia. 2009;52(8):1566‐1578.
    1. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155‐1166.
    1. Banarer S, McGregor VP, Cryer PE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes. 2002;51(4):958‐965.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する